Tweets
Than et al. Delay in starting MTX by 1 month in RA no impact on 1 year disease activity or structural outcomes. @RheumNow #ACR22 Abstr#1960 https://t.co/Kn2kHlQFpA https://t.co/EyfofVySC9
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Just so good to see PMR on the plenary stage at #ACR22, after #EULAR2022 too
SAPHYR study: sarilumab allows for
- a quicker steroid wean & less toxicity
- but also far more disease remission, quicker symptom resolution, better quality of life
Game-changing.
ABST1676 @RheumNow https://t.co/ZVqlMNoniu https://t.co/Fv3VRZrKGe
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Intersting discussion post Plenary this AM
- Agree w/RS that we should taper steroid
- Is there a disease modifying benefit? I think not
- When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred
#ACR22 @RheumNow https://t.co/ylGXk2sca7
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Study shows no progressive increase of MRI structural lesions in SI joints of health individuals with increasing age, including:
Bone marrow edema, erosions, fat lesions
Abs#2258 @RheumNow #ACR22 https://t.co/W2dkRCAPc4
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
SSc and DM/PM can cause disease related sexual dysfunction ➡️ consider pelvic floor PT
Abstract #0940 #ACR22 @RheumNow
🧘♀️8 week PT program targeting pelvic floor exercises and MSK issues impacting sexual function
🧘Women experienced sig. improved sexual function and QOL
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Ab1677 #ACR22 by @MaxKonigMD
Chimeric autoAg T cell recepter (CATCR) reprogram T cells to selectively kill autoreactive B cells
Model CATCR for APLS via B2GPI-CATCR T-cells eliminating anti-B2GP DI B cells, dose-dependent
Model for SELECTIVE Rx in APLS/rheum disease
@RheumNow https://t.co/jMpMu10phL
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Very cool preclinical plenary @MaxKonigMD
Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells)
Early days but super interesting possibilities - APS, SLE, AAV, & more?
#ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies:
precision cellular therapy
selectively deplete autoreactive B cells
@MaxKonigMD in the plenary:
CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells
#ACR22 @RheumNow https://t.co/5ZLocrwqKY
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
